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Summary 
The Apo-1/Fas antigen (CD95) mediates programmed cell death of lymphocytes when bound 
by Fas ligand or anti-Apo-1/Fas antibody. In contrast, the CD40 antigen provides a potent ac- 
tivation and survival signal to B lymphocytes when it is engaged by its T  cell ligand (CD40L, 
gp39) or cross-linked by anti-CD40 antibody. In this study, we use human tonsillar B cells and 
the Ramos Burkitt's lymphoma B cell line, which serves as a model for human germinal center 
B lymphocytes, to study the effectors of Apo-1/Fas expression and apoptosis of human B cells. 
We found that Apo-1/Fas expression was upregulated on both malignant and normal human B 
lymphocytes after CD40 ligation induced by (a) cognate T  helper-B cell interaction mediated 
by microbial superantigen  (SAg);  (b)  contact-dependent interaction with  CD40L  +,  but  not 
CD40L-Jurkat mutant T cell clones; and (c) monoclonal anti-CD40, but not any of a panel of 
control antibodies. Enhanced B cell Fas/Apo-1 expression is functionally significant. Coculture 
of Ramos Burkitt's lymphoma line cells with irradiated SAg-reactive CD4 + T  cells with SAg 
or CD40L  + Jurkat T  cells results in B  cell apoptosis, evidenced by reduced cell viability and 
DNA laddering. This process is augmented by the addition ofanti-Apo-1/Fas monoclonal an- 
tibody, consistent with an acquired susceptibility to Apo-1/Fas-mediated apoptosis. These data 
support an immunoregulatory pathway in which seemingly contradictory signals involving the 
B cell proliferation/survival antigen CD40, as well as the Apo-1/Fas molecule, which mediates 
programmed cell death oflymphocytes, are linked in the process of human B cell activation. 
Po-1/Fas (CD95) is a 48-kD cell surface antigen of the 
TNF/nerve growth factor (NGF) 1 receptor superfam- 
ily that  mediates  apoptosis  of T  and  B  lymphocytes  (1). 
The  interaction  of Apo-1/Fas  and  its  ligand  have  been 
shown  to  play  a  central  role  in  the  regulation  of pro- 
grammed cell death of mature peripheral murine and hu- 
man T lymphocytes. Defects in both Fas and its ligand have 
been  described in  murine  models  of lymphoproliferative 
disease  characterized by features of SLE  (2-4),  suggesting 
that this pathway may be responsible for the deletion ofau- 
tAbbreviations used in this paper: CD40L, CD40 ligand; MAM, Mycoplasma 
arthritidis-derived microbial  superantigen; MHC II, MHC class II; NGF, 
nerve growth factor; SAg, microbial  superantigen; TSST-1, toxic shock 
syndrome toxin 1; TMAMxr,  irradiated  MAM-reactive  CD4  § cells; TTSSTxF, 
TSST-l-reactive  CD4 + cells. 
toreactive clones. In peripheral T  lymphocytes, TCR sig- 
naling  leads  to  upregulation  of Apo-1/Fas  and,  on  Thl 
cells,  Fas ligand  expression, resulting in fratricide or even 
suicide of antigen-activated T  cells (5-8). Although Apol/ 
Fas  expression  occurs  early  after  antigen  stimulation, 
susceptibility  to  Apo-1/Fas-mediated  apoptosis  develops 
slowly (9),  allowing for the clonal expansion and effector 
function of antigen-activated T  cells before their apoptotic 
elimination. B lymphocytes also express the Apo-1/Fas re- 
ceptor (10,  11), and they are induced to undergo apoptosis 
when  bound  by Fas  ligand,  which  is  secreted selectively 
from Thl cells (12,  13). The observations that the mAb to 
human Apo-1/Fas can induce apoptosis of B lymphoblas- 
toid tumor cells in vitro (14) and ofxenografted human B 
cell tumors in vivo (15) suggest that the Apo-1/Fas signal- 
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cell tumors. 
The  CD40  antigen is a  50-kD  cell surface protein,  also 
of the TNF/NGF  receptor superfamily, which promotes B 
cell proliferation and survival. Germinal center B  cells can 
be rescued from spontaneous apoptosis in vitro by soluble 
anti-CD40 mAb (16). When engaged by the T  cell activa- 
tion molecule CD40L (gp39) or when cross-linked by anti- 
CD40  antibody, CD40  induces  a  potent B  cell activation 
signal (17,  18)  that is characterized by expression of activa- 
tion  antigens  (19,  20),  increased DNA  synthesis  (21),  ty- 
rosine kinase activity (22), and Ig class switching (23-25). 
The need to control the magnitude and duration of hu- 
moral  immune  responses  after  antigenic  stimulation  sug- 
gests that  the  pathways  of B  cell activation and  apoptosis 
may be  closely linked.  In this study, we  demonstrate that 
cognate Th-B  cell interaction mediated by CD40  ligation 
leads to marked upregnlation of Apo-1/Fas expression on 
normal  and  malignant  human  B  lymphocytes.  Using  the 
Burkitt's lymphoma Ramos B  cell line as a model of germi- 
nal center B  cells (26, 27), we demonstrate that this interac- 
tion both  upregnlates Apo-1/Fas expression and facilitates 
susceptibility to Apo-1/Fas-mediated programmed cell death. 
Materials and Methods 
Cell Culture.  B cells were isolated from fresh human tonsils as 
described previously (28). Briefly, T  cells were eliminated by ro- 
setting overnight with SRBCs, and the isolated B cell population 
was frozen in liquid nitrogen and cryopreserved at -70~  B cells 
were thawed, washed, and cultured in C50 medium (RPMI 1640 
medium with penicillin, streptomycin, glutamine, and 10% fetal 
bovine serum).  The Burkitt's lymphoma Ramos B  cell line was 
obtained from  American  Type  Culture  Collection  (Rockville, 
MD) and grown in C50 as described above. Mutant clones of the 
Jurkat  lymphoblastoid T  cell lines B2.7  and D1.1  were  kindly 
provided by Dr. Seth Lederman (Columbia University College of 
Physicians and Surgeons,  New York,  NY).  B2.7  is deficient in 
CD40L  expression,  while  clone  D1.1  constitutively expresses 
CD40L  (17,  29),  which were  confirmed by staining with anti- 
body to  CD40L  (Genzyme Corp.,  Cambridge,  MA).  As indi- 
cated, cells were cultured in the presence of highly purified Myco- 
plasma arthritidis-derived microbial superantigen (SAg) (MAM) at 
a  final concentration of 1:80,000  of stock solution, which was 
generously provided by Dr. B. Cole (University of Utah College 
of Medicine, Salt Lake City, UT)  (30), or toxic shock syndrome 
toxin-1  (TSST-1)  at a  final concentration of 10  ng/ml  (Toxin 
Technology, Sarasota, FL). 
Coculture experiments were performed using 106 B cells and 
2  ￿  105  irradiated  MAM-  or  TSST-l-reactive  CD4 +  cells 
(TM^M￿  or TrssTxr, respectively), or with Jurkat T cells (B2.7xr or 
Dl.l￿  in a final volume of 1 ml C50  media. After irradiation 
with 500  (SAg-reactive T  cells) or 1,000  rads  (Jurkat  mutants), 
the T  cells were still functional in cognate interaction, as assessed 
by CD23 and Apo-1/Fas induction on the B cells, but they died 
in  culture  within  24-48  h,  as  determined  by  FACS  |  analysis 
(Becton Dickinson &  Co.,  Mountain View, CA) of viable cells 
for B and T cell markers. 
mAbs.  Sterile antibodies used in cell culture experiments in- 
clude anti-human Fas (murine IgM; Upstate Biotechnology Inc., 
Lake Placid,  NY)  used  at  100  ng/ml,  and  anti-CD40  (mouse 
IgGIK, clone  B-B20;  Biosource  International,  Camarillo,  CA), 
anti-CD40L  (Genzyme),  anti-CD71  (anti-transferrin  receptor, 
mouse IgG~; Biosource), anti-CD54  (anti-ICAM; AMAC Inc., 
Westbrook,  ME),  and  anti-CD37  (mouse  IgG2a; Biosource), 
W6/32  (anti-MHC  I),  NAMBI  (anti-i32-microglobulin), and 
L-243 (anti-MHC class II [MHC II]; gift of Dr. Carlo Russo, Cor- 
nell University Medical College), OKT3  (mouse IgG2a; ATCC), 
anti-CD20  (PharMingen,  San Diego, CA), and anti-CD23  IgG 
(EBVCS2;  ATCC)  or anti-CD23  IgM  (EBVCS3;  ATCC).  For 
culture, these antibodies were used at  1 ~zg/ml unless  otherwise 
specified. Directly conjugated antibodies used in cell staining ex- 
periments include anti-Apo-l-biotin (IgG3K) or anti-Apo-l/Fas- 
FITC  (IgG1; Immunotech,  Inc., Westbrook, ME), B1  (Coulter 
Immunology,  Hialeah,  FL),  anti-CD19-FITC  (PharMingen), 
and anti-CD4-biotin (PharMingen).  For blocking experiments, 
an F(ab)'2 preparation of the anti-Apo-I lgG3K antibody was used 
at 200 ng/ml (5). 
Indirect Immunofluorescence  Analysis.  Cells were washed in cold 
HBSS and stained in primary antibodies (or control, 1% BSA in 
PBS with azide) for 45 min at 4~  Cells were washed 35< in cold 
HBSS,  incubated with secondary antibodies or FITC-avidin, as 
indicated, for 25 rain at 4~  and then washed 3￿  again in cold 
HBSS. Alternatively, cells were washed in cold HBSS and stained 
with a single, directly conjugated primary antibody before wash- 
ing  3￿  before  analysis.  Cell  fluorescence  was  analyzed on  a 
FACScan  |  (Becton  Dickinson)  and  analyzed  with  CellQuest 
(Becton Dickinson). 
Superantigen-reactive CD4  + T  Cell Lines.  As described previ- 
ously (29), PBL from normal donors were cultured at 2 X 10r 
in the presence of highly purified MAM at a final dilution of 1  : 
80,000 or TSST-1 at a final concentration of 10 ngm/ml. After 
3 d, the cultures were supplemented with human IL-2 (Schiappa- 
relli, Columbia, MD),  and 1 d later, blast and resting cells were 
separated by Ficoll gradient centrifugation. Purified CD4 + T cells 
were obtained by immune rosette depletion ofCD8 + cells. These 
CD4 +,  SAg-reactive, T  cell lines (TMA  M or TTSST  )  were frozen 
-70~  After thawing  and  washing,  they  were  grown  in  the 
presence of IL-2, and periodically expanded by retriggering with 
the relevant SAg in the presence of irradiated, autologous non-T 
cells. 
Viability Assay.  Aliquots of cultured cells were diluted ] :4 in 
0.4% trypan blue and were analyzed for the exclusion of dye by 
light microscopy. 
DNA Analysis.  After 2 d of culture with irradiated CD4 + T 
cells, viable B  cell populations were purified by Ficoll Hypaque 
centrifugation. These cells were cultured for an additional 16 h in 
the presence of media alone, anti-Apo-1/Fas IgM or anti-CD23 
IgM  at  a  concentration  of 200  ng/ml.  Low  molecular weight 
DNAs prepared from  106  cells by lysis in 20  I.~1 buffer (10  mM 
EDTA, 50 mM Tris-C1, pH 8.0,  0.5% SDS, 0.5 mg/ml protein- 
ase K) at 50~  for 1 h, followed by the addition ofRNAse A (0.5 
mg/ml) at 50~  for 1 h. After heating (70~  5 min), DNAs were 
analyzed by 1.6%  agarose gel electrophoresis in the presence of 
ethidium bromide  (0.16  ~g/ml),  and  they were  photographed 
under UV light. 
Results 
Cognate  Th-B  Cell Interactions  Upregulate Apo-I /Fas  Ex- 
pression on Human Tonsillar and Ramos B  Cells.  To investi- 
gate the effect of Th-B cell interaction on B  cell Apo-1/Fas 
1558  CD40 Ligation Induces Apo-1/Fas Expression on Human B Lymphocytes pression,  tonsillar  B  lymphocytes  were  cocultured  with 
CD4 + TMAMx  r  in the presence  of MAM.  Flow cytometric 
analysis of the B  cell populations was performed after 48 h 
of culture. The tonsillar B  cells constitutively express a rel- 
atively low level of Apo-1/Fas, which is augmented by the 
Sag bridge  (Fig.  1 A). As shown  in Fig.  1  B,  this  effect is 
specific, since TSST-reactive CD4 §  T  cells are effective in 
upregulating Apo-1/Fas expression only in the presence of 
TSST-1,  and not when non-cross-reactive SAg (MAM) is 
present in the culture system. 
To  study the  effect of cognate  T-B  cell interaction  on 
Apo-1/Fas  expresssion  in  a  more  homogeneous  target  B 
cell  population,  we  focused  on  the  Burkitt's  lymphoma 
P.amos  B  cell line.  Burkitt's lymphoma  cell lines  such  as 
kamos  bear phenotypic and  functional  similarities to  hu- 
man  germinal center B  cells (26,  27).  As shown  in  Fig. 2, 
although  there  was  modest  upregulation  of  Apo-1/Fas 
when the B  cells were cultured with SAg-reactive CD4 + T 
cells  alone,  Apo-1/Fas  expression  was  dramatically  in- 
creased on  Ramos  B  cells cultured with  both  MAM  and 
TMAMxr. 
Apo- I /Fas Expression  on B  Cells Is Facilitated by the Interac- 
tion  of  CD40  with  Its  T  Cell  Ligand,  CD4OL.  Cognate 
Th-B cell interaction is mediated, in large measure, by sig- 
nals delivered to the B  cell by the  CD40  antigen (17).  To 
investigate the role of CD40  ligation in T  cell-induced B 
cell Apo-1/Fas expression, we used two well-characterized 
mutant clones of the Jurkat T  cell line (17, 29). Clone D 1.1 
cells constitutively express high levels of gp39,  the physio- 
logic ligand of CD40  (CD40L),  while clone B2.7  is defi- 
cient in CD40L expression. As shown (Fig. 3), coculture of 
P,  amos B  cells with the CD40L + Jurkat clone, but not the 
CD40L-  Jurkat  clone,  induced  marked  upregulation  of 
Apo-1/Fas expression on B  cells. Similar results were  ob- 
tained using tonsillar B  lymphocytes (data not shown).  In 
Figure  1.  Superantigen-induced cognate T-B cell signaling  upregulates 
Apo-1 expression on tonsillar B lymphocytes. (A) Flow cytometric analy- 
sis (FACS  |  of human tonsillar B cells cultured for 48 h with (a) media or 
(b) CD4 + TMAM~,r  in the presence of MAM. Cells were stained with a bi- 
otin-conjugated antibody to Apo-1, followed by FITC-avidin (shaded ar- 
eas), or with  a biotin-conjugated  control antibody, followed by FITC- 
avidin (unshaded areas). The mean channel fluorescence for each Apo-1 
stain is indicated. At the time of analysis,  >99% of the gated cells  were B 1 
positive, and <1% were CD4 positive. (B) Tonsillar B cells were cocul- 
tured with media, MAM, TSST-1, TvssT,~, MAIM + TTssvx~  , or TSST-1 + 
"FTssT~, and were analyzed for Apo-1/Fas expression by flow cytometry. 
The  increase in  mean  channel fluorescence of Apo-1/Fas staining is 
shown relative to a mean channel fluorescence of 58, which was observed 
for the tonsillar B cells cultured with media alone. 
expression, we  took advantage of the  dual affinity of SAg 
for MHC  II molecules and particular TCR-[3  chain vari- 
able gene products (31, 32). These properties allow SAg to 
facilitate a nonphysiologic form of cognate Th-B cell inter- 
action between  SAg-bearing B  cell populations  and  SAg- 
reactive CD4 + T  ceils (33).  To determine if SAg-mediated 
Th-B  interaction  would  influence  B  cell Apo-1/Fas  ex- 
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Figure 2.  Superantigen-induced cognate T-B cell signaling  upregnlates 
Apo-1  expression on Ramos  B lymphocytes. Flow cytometric analysis 
(FACS  |  of R.amos B cells cultured for 72 h with (A) media, (B) MAM, 
(C) CD4 + TM~aVlxr, or (D) MAIM +  CD4 + TMAMx~. Cells were stained 
with a biotin-conjugated antibody to Apo-1, followed by FITC-avidin 
(shaded areas) or with a biotin-conjugated control antibody followed by 
FITC-avidin  (unshaded areas). The mean channel fluorescence for each 
Apo-1 stain is indicated. At the time of analysis, >99% of the gated cells 
were B1 positive, and < 1% were CD4 positive. Figure  3.  Apo-1 expression is induced  on Ramos B cells by CD40L + 
Jurkat T  cells, but not CD40L- Jurkat T  cells. Ramos B cells were cul- 
tured  for 48 h  with  (/t)  media  alone,  (/3) with CD40L- Jurkat T  cells 
(B2.7￿  or (C) with CD40L  + Jurkat T  cells (Dl.lxr),  and stained with a 
biotin-conjugated  antibody  to Apo-1  followed  by FITC-avidin (shaded 
areas), or with a biotin-conjugated  control antibody  followed  by FITC- 
avidin  (unshaded areas). The mean  channel  fluorescence  for each Apo-1 
~tain is indicated. At the time of analysis, >99% of the gated cells were B1 
positive, and <1% were CD4 positive. 
addition,  phenotypic  analysis ofRamos  B  cells cultured for 
48 h  with the Jurkat mutants  (Fig. 4)  demonstrated  that in- 
creased  Apo-1/Fas  expression  occurs  in  concert  with  en- 
hanced expression of other CD40-inducible  cell surface an- 
tigens  including  B7,  CD23,  MHC  II,  and  CD54.  CD19 
and CD71  expressions were not affected. Experiments per- 
formed  using mAb to  CD40L  demonstrate  that  the induc- 
tion of Apo-1/Fas by CD40L + Jurkat T  cells is impeded by 
antibody to CD40L  (Table  1). 
To  assess  the  requirement  for  cell-cell  contact  in  this 
response,  two-chamber  experiments  were  performed  in 
Figure 4.  Activation  antigen expression on Ramos B ceils after cocul- 
ture  with CD40L- and  CD40L + Jurkat T  cells. Ramos cells were cul- 
tured  with CD40L  Jurkat  T  cells (B2.7xr) or CD40L + Jurkat  T  cells 
(D 1. l￿  for 48 h and then analyzed by indirect immunofluorescence  with 
a panel of mAbs, as indicated. 
which  B  cells were  separated  from  Th  cells by  a  semiper- 
meable  membrane.  Ramos  B  cells  were  cultured  in  the 
lower  chambers  o15 wells  with  cytokine-permeabte  inserts 
(upper chambers)  containing irradiated DI. 1 or B2.7 Jurkat 
T  cells with  and  without  Ramos  B  cells.  As shown  (Table 
2),  Apo-1/Fas  was  induced  on  Ramos  cells  only  when 
Table  1.  Apo-1  Induction  on Ramos B cells by CD40L +  Jurkat Mutants Is Inhibited by Antibody  to CD40L 
Cell culture  % + 
B cell Apo-1/Fas expression 
Mean channel fluorescence 
Ramos  +  media 
Ramos  +  media  +  anti-CD40L 
Ramos  +  media +  anti-MHCl 
Ramos  +  D 1.1~ 
Ramos  +  Dl.l￿  +  anti-CD40L 
Ramos  +  Dl.l~r +  anti-MHC I 
16  27 
18  28 
17  27 
83  100 
19  28 
83  96 
5 ￿  10  s Ramos B cells were cultured with media alone or with 10  s irradiated  CD40L + Jurkat T cells (DI.I,D for 48 h in the presence  or absence of 
blocking antibody (anti-CD40L), or a control antibody (anti-MHC I, W6/32), each at a concentration of 1 ~g/ml. 
1560  CD40 Ligation Induces Apo-1/Fas Expression on Human B Lymphocytes Table 2.  Apo-1 Induction on Ramos B Cells Requires Direct Contact with DC4OL+  Jurkat Mutants 
Upper chamber  Lower chamber  % + 
B cell Apo-1/Fas expression 
Mean channel fluorescence 
Media  R.amos  10  28 
CD40L- Txr  P,  amos  14  28 
CD40L- Txr  + R.amOSxr  tLamos  17  28 
Media  ILamos + D 1.1 ~r  52  59 
CD40L  + Txr  R.amos  12  26 
CD40L  § Txr+tkamos~r  tkamos  10  26 
5  ￿  10  s 1Lamos B  ceils were cultured with media alone or with  10  s irradiated,  CD40L + Jurkat T  cells for 48 h. Each well (lower chamber) con- 
rained a cytokine-permeable insert (upper chamber) with  105 irradiated CD40L-  (B2.7xr)  or CD40L  +  (Dl.lxr) Jurkat mutants with or without 10  s 
irradiated Ramos cells (tkamos,~), as indicated.  Flow cytometry for Apo-1 expression on cells in the lower chamber was performed at 48 h.  In the 
well with both tkamos and Dl.lxrJurkat ceils in the lower chamber, 94% of the cells were B1 +, and 0.9% were OKT3  + at the time of analysis. 
CD40L  +  DI.1 Jurkat  T  cells  were  directly present  in  the 
lower chamber.  There was no induction of Apo-1/Fas ex- 
pression  on ILamos cells in the lower chamber when B2.7 
or D1.1  cells were present in the inserts,  even when irradi- 
ated P.amos cells  were added to the insert.  The specific in- 
duction of Apo-1/Fas by the CD40L  § mutant Jurkat T  cell 
line,  in a process that requires  direct cell-cell contact, sup- 
ports  the  conclusion  that  CD40L-CD40  binding  is  suffi- 
cient for the upregulation of  Apo-1/Fas on human B  cells. 
Soluble  mAb  to  CD40  Induces Apo-1/Fas  Expression  on 
Normal and Malignant Human B  Lymphocytes.  To  examine 
directly whether ligation of CD40 enhances B  cell Apo-1/ 
Fas  expression,  tonsillar or P.amos B  cells were cultured in 
the  presence  of  anti-CD40  or  a  control  antibody  and 
stained  for Apo-1/Fas  expression.  As  shown  in  Fig.  5  A, 
soluble anti-CD40 antibody upregulates Apo-1/Fas expres- 
sion on tonsillar B  cells during a 48-h period. Experiments 
using  the  tLamos  system  demonstrate  that  this  effect  is 
dose-dependent  and occurs over a wide range of antibody 
concentrations  (Fig.  5  B).  Specificity  of CD40  signaling 
was  supported  by  the  lack  of Apo-1/Fas  induction  after 
treatment of Ikamos B  cells with a panel of mAbs to other 
B cell surface molecules, including MHC I, MHC II, and B7. 
The Induction of Apo-1/Fas by Cognate T-B Cell Signaling 
Correlates with B  Cell Apoptosis In  Vitro.  One  of the  most 
striking  features  of these  experiments  was  the  consistent 
observation  that  after  cognate interaction  with  SAg-reac- 
tive  CD4 +  T  cells,  a  significant  fraction  of both  tonsillar 
and R.amos B  cells  died in culture  (Table  3).  To examine 
the mechanism of B  cell death after CD40 ligation and in- 
creased Apo-1  expression,  Ramos B  cells were cocultured 
with irradiated  CD40L-  (B2.7xr)  or CD40L  +  (Dl.lxr)Jur- 
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Figure  5.  Apo-1  induction on human 
B  cells by soluble antibody to CD40. (A) 
Human  tonsiUar  B  cells  were  cultured 
with  media  alone  (a)  or  with  mAb  to 
CD40.  After  24  (b)  and  48  h  (c), cells 
were  stained  using  a  biotin-conjugated 
antibody to Apo-1 (shaded areas) or with a 
biotin-conjugated  control  antibody  (un- 
shaded  areas)  followed  by  FlTC-avidin. 
(/3)  Apo-1  expression  is  specifically  in- 
duced  on  Ramos B  cells  by anti-CD40 
antibody  in  a  dose-dependent  manner. 
Ramos B  cells were cultured in the pres- 
ence of media alone or with serial dilu- 
tions ofanti-CD40 or and-CD71 ranging 
from  2  I~g/ml  to  10  ng/ml,  and  they 
were stained for Apo-1 expression using a 
direct  FITC-conjugated  anti-Apo-1/Fas 
mAb. m, anti-CD40; O, anti-CD71. Table 3.  Cognate  Signaling  Induced  by Superantigen  or by 
DC40L +  Jurkat T  Cells Is Associated  with B  Cell Death 
Culture conditions  Viability at 48 h 
Tonsillar B cells +  media 
Tonsillar B cells +  CD40L- Txr 
Tonsillar B cells +  CD40L + Txr 
Tonsillar B cells +  MAM +  CD4 + TMAMx  r 
1Kamos +  media 
Ramos +  Jurkat CD40L- Txr 
Ramos +  Jurkat CD40L + Txr 
Kamos +  MAM 
1Kamos +  CD4 + TMAMx  r 
1Kamos +  MAM +  CD4 + TMAM~r 
50% 
20% 
<5% 
<1% 
76% 
69% 
41% 
60% 
84% 
16% 
Tonsillar or Ramos B cells were cultured under conditions as indicated, 
and assessed  for viability by trypan blue exclusion after 48 h. These re- 
suits are representative of three separate experiments. 
kat mutants, or CD4 + TM~xr in the presence or absence of 
MAM.  After 48  h,  viable B  cells were  isolated from  each 
culture  by  Ficoll-Hypaque  gradient  centrifugation.  After 
overnight incubation with  medium,  IgM anti-Apo-1/Fas, 
or IgM anti-CD23 as control, low molecular weight DNAs 
were  isolated  and  assessed  for  fragmentation  (Fig.  6).  As 
shown,  1Lamos  B  cells  cultured  with  CD40L-  Jurkat  T 
cells do not exhibit DNA fragmentation. In the case of R.a- 
mos B  cells cultured with CD4 + TMAMxr in the absence of 
MAM,  modest  upregnlation  of Apo-1/Fas  antigen  is  in- 
duced (Fig. 2  C)  and DNA  fragmentation occurs after the 
addition  of anti-Apo-1/Fas,  but  there  is  no  spontaneous 
apoptosis. In contrast, Ramos B  cells cultured with D1.1xr, 
or CD4 + TMAMxr in the presence of MAM,  are induced to 
undergo apoptosis. This process is augmented by the addi- 
tion of IgM anti-Apo-1/Fas antibody, but not of the iso- 
type-matched control antibody. Pretreatment of the Apo- 
1/Fas-expressing 1Lamos  B  cells  with  a  blocking  F(ab)2' 
preparation  of the  anti-Apo-1  IgG3K  antibody  abrogated 
this effect (Table 4  B). Taken together, these results suggest 
that  cognate  signaling  through  the  CD40  pathway  both 
upregnlates  Apo-1/Fas  expression  on  B  cells  and  renders 
these B  cells susceptible to Apo-1/Fas-mediated apoptosis. 
Discussion 
The present report provides evidence for a new outcome 
of CD40  signaling. Upregnlation of Fas/Apo-1 antigen on 
normal and malignant human  B  cells occurs after (a)  cog- 
nate Th-B  cell interaction mediated by SAg; (b)  coculture 
with  CD40L +  but not CD40L- Jurkat T  cell line mutant 
clones;  or  (c)  soluble  anti-CD40  mAb.  Enhanced  B  cell 
Fas/Apo-1  expression  after  CD40  ligation  is  functionally 
significant.  Coculture  of R.amos  Burkitt's lymphoma  line 
cells with irradiated SAg-reactive CD4 +  T  cells with  SAg 
or CD40L + Jurkat T  cells resulted in B  cell apoptosis, dem- 
onstrated  by  reduced  cell  viability and  DNA  laddering. 
This process was augmented by the addition of anti-Apo  1/ 
Fas mAb, consistent with an acquired susceptibility to Apo- 
1/Fas-mediated apoptosis. These data support an immuno- 
regulatory pathway in which  seemingly contradictory sig- 
nals  involving  the  B  cell  proliferation/survival  antigen 
CD40  and  the  Apo-1/Fas  molecule  that  mediates  pro- 
Figure 6.  Cognate  T-B cell sig- 
naling induces apoptosis of Ra- 
mos B cells and renders them sus- 
ceptible to  Apo-1/Fas-mediated 
apoptosis. R.amos B  cells were 
cultured for 48 h with  irradiated 
CD40L-  (B2.7~r, lanes 1-3)  or 
CD40L + (Dl.l~r, lanes 4-6)Jur- 
kat mutants, with  CD4 + TMAMx  r 
without  (lanes 7-9),  or  with 
(lanes I0  and  11)  MAM.  After 
Ficoll  Hypaque  centrifugation, 
viable IKamos B  cells were  cul- 
tured overnight after the addition 
of media  (1,  4,  7),  anti-Apo-1 
mAb (2, 5, 8, 10), or anti-CD23 
(3, 6, 9, 11), each at a concentra- 
tion of 200 ng/ml,  and low mo- 
lecular weight  DNAs were  pre- 
pared and analyzed by ethidium 
bromide  agarose gel  electro- 
phoresis. Molecular weight mark- 
ers are indicated. 
1562  CD40 Ligation Induces Apo-1/Fas Expression  on Human B Lymphocytes Table 4.  Cognate  Signaling Induced by Superantigen or by CD40L  +  Jurkat  T Cells Confers Susceptibility to Apo- 1/Fas-mediated 
B Cell Death 
Viability at 72 h 
(media or antibody added after 48 h) 
Culture conditions  Media  Anti-Apo-  1  Anti-CD71 
A. Ramos +  media 
R.amos +  CD40L- Txr 
Ramos +  CD40L  + Txr 
Ramos +  MAM +  TM^M~ 
B. Ramos +  CD40L- Txr 
Ramos +  CD40L  + Txr 
Ramos +  T~a~,~ 
R.amos +  MAM +  T~r 
83%  76%  72% 
77%  65%  77% 
60%  18%  77% 
52%  22%  70% 
Anti-Apo-  1 
Media  Media  F(ab)2'  anti-Apo-1 
79%  81%  78% 
70%  42%  64% 
67%  60%  77% 
10%  0%  12% 
(A) ILamos B cells were cultured as indicated for 48 h, after which cultures were supplemented with media, mAb to Apo-1/Fas (200 ng/ml), or with 
antibody to CD71 as a control. ARer an additional 24 h, each culture was assessed for viability by trypan blue exclusion. (B) R.amos B cells were cul- 
tured as indicated for 48 h, after which cultures were supplemented with media alone or with an mAb to Apo-1/Fas (200 ng/ml), in the presence or 
absence of  an F(ab)2', nonsignaling preparation of  antibody to Apo-1/Fas, also at a concentration of  200 ng/ml. After an additional 24 h, each culture 
was assessed for viability by trypan blue exclusion. 
grammed cell death  of lymphocytes are linked in the pro- 
cess of human B  cell activation. 
Productive  B  cell  activation  requires  the  delivery  of at 
least two signals, the binding of antigen to surface Ig recep- 
tors (signal 1), followed by cognate interaction with an an- 
tigen-specific  T  cell  (signal  2)  (34,  35).  The  studies  re- 
ported here  suggest that in the absence of slg signaling,  B 
cells  stimulated  via  CD40  upregulate  Apo-1/Fas  and  are 
prepared  for  the  delivery  of death  signals.  This  pathway 
could serve to eliminate bystander B  cells that are inappro- 
priately  activated.  Presumably,  a  B  cell  that  has  received 
both signals 1 and 2 would be resistant to this form of elim- 
ination  and  respond  by  proliferation  and  differentiation 
into  an  antibody-forming  cell.  Consistent  with  this  hy- 
pothesis,  we have determined  that cross-linking of surface 
Ig on Ramos B  cells by anti-IgM antibody does not affect 
Apo-1/Fas expression induced by CD40 ligation, but does 
render these  cells resistant  to apoptosis  (Schattner,  E.,  un- 
published data). 
The results described in this study must be considered in 
the  context  of previous reports  from our laboratories  and 
others that direct T  cell help for B  cell activation mediated 
by  allospecific  T  cell  lines  or  SAg-induced  Th-B  cell 
bridge  can  result  in  polyclonal activation  of both  human 
and murine  B  cells  (29,  36-38).  Heterogeneity  in the  re- 
sponse of B  cell subpopulations to CD40 ligation may be a 
factor in determining the outcome of the Th-B cell inter- 
action.  For  example,  it  is  the  high  density,  resting B  cell 
subset  that  expresses  the  activation  antigen  CD23  in  re- 
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sponse to cognate Th-B cell interaction (39). An additional 
determinant  of the B  cell's fate may be the relative  abun- 
dance of Thl and Th2 cells in culture. Thl cells secrete cy- 
tokines central to the cellular immune response, such as IL-2 
and IFN-~/(40), and they selectively express Fas ligand after 
activation  (12),  while  CD4 +  Th2  cells  secrete  cytokines 
that  support  the  humoral  immune  response.  A  role  for 
CD4 +  Thl  cells  in  Apo-1/Fas-mediated  B  celt  death  is 
consistent with this functional dichotomy, and it supports a 
mechansim  other  than  antagonistic  cytokine  effects  by 
which Thl cells can downregulate B cell responses. The as- 
sociation of defects in the Fas/Apo-1/Fas ligand pair in the 
development of SLE-like disease  in several strains  of mice 
(2-4)  suggests  that  this  pathway  may be  involved in  the 
control  of autoreactive  B  cells.  SAg-mediated,  CD4 +  T 
cell-induced B  cell apoptosis should provide a model sys- 
tem for assessing the integrity of this signaling pathway in 
human SLE. 
Our data suggest a possible mechanism for the develop- 
ment  of B  cell  lymphomas  in  patients  with  X-linked 
hyper-IgM,  an  immunodeficiency  syndrome  defined  by 
molecular defects in the T  cell ligand for CD40 (41, 42). In 
these patients,  impaired signaling through CD40 might al- 
low  for  uncontrolled  B  cell  expansion  due  to  a  lack  of 
CD40L-mediated  upregulation  of Apo-1/Fas  on  B  cells. 
This  signahng  pathway,  which  primes  B  cells  for  CD4 + 
cell-mediated B  cell apoptosis, may also relate to the high 
incidence  of B  cell lymphomas among patients  with  HIV 
disease, where a high proportion of tumors are of Burkitt's or Burkitt's-like (small, noncleaved cell) subtypes (43), sim- 
ilar to those of the Ramos B  cell line used in our experi- 
ments.  In HIV disease, the progressive decline of CD4 + T 
cells would diminish the capacity for Apo-1/Fas induction 
on B cells via the CD40L T  cell-dependent pathway we have 
described. Moreover, the reduction ofCD4 + T  cells and shift 
from a Thl- to Th2-dominant population would specifically 
deplete the  host  of those  T  cells that  express  and  secrete 
human Fas ligand and are responsible for Fas-mediated B  cell 
cytotoxicity. In that setting, B  cell malignancies would arise 
due to a lack of CD4 + T  cell-mediated induction of Apo- 
1/Fas, with subsequent failure orB cell apoptosis. 
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Note Added in Proof: While this manuscript was under review, another group reported similar findings that 
CD40 ligation results in increased B cell Fas expression in a murine system (Rothstein, T. L., J. K. Wang, 
D.J. Panka,  L. C. Foote, Z. Wang, B. Stanger,  M. Cui, S-T. Ju, and A. Marshak-Rothstein. 1995. Nature 
(Lond.).  374:163-165).  Subsequently,  as reported in this issue, Garrone et al. have observed findings similar 
to ours in human B lymphocytes (see pp. 1265-1273). 
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